BPC-157 vs Chrysalin
Research Verdict
Chrysalin is the stronger research reference for the stated comparison criteria. Chrysalin (TP508): Phase 2 human trial data for diabetic foot ulcers and bone fracture repair (Stiernberg et al.) showing acceleration of wound healing.
Quick Answers
Which is better, BPC-157 or Chrysalin?
Chrysalin is the stronger research reference for the stated comparison criteria. Chrysalin (TP508): Phase 2 human trial data for diabetic foot ulcers and bone fracture repair (Stiernberg et al.) showing acceleration of wound healing.
What is the key difference between BPC-157 and Chrysalin?
Chrysalin is a thrombin-derived peptide fragment promoting angiogenesis and stem cell recruitment; BPC-157 is a synthetic gastric peptide with broader but less validated preclinical claims - both target tissue repair but through different signaling pathways.
Evidence Comparison
Chrysalin (TP508): Phase 2 human trial data for diabetic foot ulcers and bone fracture repair (Stiernberg et al.) showing acceleration of wound healing. BPC-157: 70+ rodent studies, single research group, zero human trials. Chrysalin has the stronger evidence by virtue of having any human clinical data.
Evidence Context Favoring BPC-157
GI protection or broad tissue repair research in preclinical models where the extensive rodent literature is relevant.
Evidence Context Favoring Chrysalin
Wound healing or bone repair research where Phase 2 human data matters - Chrysalin has clinical evidence that BPC-157 lacks.
Side-by-Side Snapshot
| Evidence grade | BPC-157: Level B Chrysalin: Level C |
|---|---|
| Research status | BPC-157: Phase 2 Chrysalin: Phase 2 |
| Primary category | BPC-157: Healing & Recovery Chrysalin: Healing & Recovery |
| Cited studies | BPC-157: 10 Chrysalin: 2 |